Oklo is in a severe, sustained downtrend, with the stock down 74.88% over the past year and 55.40% year-to-date, a collapse that has taken the shares from a 52-week high of $193.84 to a current price of $34.70. At that level the stock trades at just 0.6% of its 52-week range (($34.70 - $33.70) / ($193.84 - $33.70)), essentially pinned to its 52-week low of $33.70 — a positioning that signals capitulation and momentum-driven selling rather than a value opportunity, since there is no established base of support beneath the current price. The maximum drawdown of -80.15% underscores how violent the reversal has been from the 2025 momentum peak, and with the stock sitting at the very bottom of its range, any further weakness risks a fresh leg lower into price discovery with no technical reference points.

Short-term momentum remains firmly negative and is decelerating rather than stabilizing: the stock is down 18.49% over the past month and 28.97% over three months, meaning the decline is steepening even as the one-year figure (-74.88%) already reflects a historic collapse. This creates a bearish divergence in the opposite direction of a typical reversal — the 1-month trend is worse than the 3-month trend, which is worse than the 6-month trend (-30.95%), indicating persistent, accelerating selling pressure rather than mean reversion. Relative strength confirms the underperformance: OKLO trails SPY by 20.61 percentage points over one month and a staggering 90.88 points over one year, while SPY itself gained 2.12% and 16.00% over those same periods, meaning Oklo is falling in both absolute and relative terms. Volume of roughly 7.44 million shares and a short ratio of 3.43 suggest active trading and meaningful short interest that could amplify moves in either direction.

Key technical levels are stark: immediate support sits at the 52-week low of $33.70, just $1.00 below the current $34.70 price, and a decisive breakdown below that level would signal a continuation of the downtrend with no historical floor to catch the fall. Resistance is effectively the entire prior range, with the 52-week high of $193.84 representing a 459% premium to the current price — a level that would require a complete narrative reversal to revisit. With a beta of 1.215, Oklo is roughly 21.5% more volatile than the broader market, meaning position sizing should account for amplified drawdowns; combined with the -80.15% max drawdown, this is a high-risk instrument where capital preservation is paramount and any stabilization above $33.70 would be the first sign of a potential bottoming process.

Oklo's revenue trajectory is nascent and lumpy: the company reported $1.21 million in revenue in Q2 2026 (the June 30, 2026 quarter), its first meaningful top-line figure after several quarters of zero revenue in Q1 2026, Q4 2025, Q3 2025, and Q2 2025. The Q2 2026 revenue carried a 40.41% gross margin ($489,000 gross profit on $1.21 million revenue), but with only $242,000 of that revenue disclosed as "Product and Service, Other" in the segment data, the composition is opaque and the base is far too small to support the company's valuation. The multi-quarter trend shows a company transitioning from pure R&D to early commercialization, but at a scale ($1.21 million quarterly) that is effectively immaterial against a $6.9 billion market cap, implying the investment case rests entirely on future execution rather than current fundamentals.

Profitability remains deeply negative and is worsening as the company scales spending: Q2 2026 net income was -$48.54 million (a -40.11% net margin) versus -$33.06 million in Q1 2026 and -$24.69 million in Q2 2025, meaning losses have roughly doubled year-over-year. Operating income was -$73.19 million in Q2 2026, with research and development at $39.47 million and SG&A at $34.21 million, reflecting aggressive investment in the Aurora program; the operating margin of -60.49% and EBITDA of -$51.35 million confirm that costs are running far ahead of any revenue. The one offset is interest income of $21.50 million in Q2 2026, which reduced the pre-tax loss to -$51.69 million, but this is a function of the large cash pile rather than operational progress, and the gross margin of 40.41% is not yet meaningful given the tiny revenue base.

The balance sheet is the company's strongest asset but also its dilution risk: Oklo holds $1.66 billion in cash at the end of Q2 2026, up from $788 million at year-end 2025, after raising $670 million in common stock issuance in Q2 2026 and $1.18 billion in Q1 2026. The current ratio of 49.08 and debt-to-equity of 0.00098 reflect an essentially debt-free, cash-rich structure, but free cash flow is deeply negative at -$141.68 million in Q2 2026 and -$275.82 million on a trailing-twelve-month basis, with capital expenditures of -$94.09 million in the quarter. ROE of -7.16% and ROA of -6.65% show the cash is not yet generating returns, and the reliance on equity issuance (shares outstanding grew from 146.4 million at year-end 2025 to 176.2 million in Q2 2026) means continued dilution is likely until commercialization generates cash flow.

For a pre-revenue company with negative net income of -$48.54 million and negative EBITDA of -$51.35 million in the latest quarter, the PE ratio is not meaningful (trailing PE of -99.67, forward PE of -32.21), so the appropriate primary metric is the price-to-sales ratio or EV/Sales. However, with trailing revenue of only $1.21 million, the PS ratio is effectively undefined (reported as 0) and the EV/Sales ratio is an astronomical 3,280.68x, reflecting a $6.9 billion market cap against negligible revenue — a valuation that can only be justified by future revenue that does not yet exist. The forward PE of -32.21 versus trailing PE of -99.67 implies the market expects losses to narrow, but the gap is driven by expected revenue growth (analyst estimated revenue average of $314.73 million) rather than current profitability.

Peer comparison is difficult because Oklo's valuation multiples are not comparable to operating utilities or even profitable nuclear peers: the price-to-book ratio of 7.11x is elevated versus the independent power producer sector, where mature utilities typically trade at 1.5x to 2.5x book, and the EV/EBITDA of -88.59 is negative and therefore meaningless. Against SMR peers like NuScale and BWX Technologies, Oklo trades at a premium on a price-to-book basis despite having no revenue, no regulatory approval, and a 2028+ commercialization timeline, suggesting the market is pricing in a best-case execution scenario. The premium is not justified by current fundamentals — it reflects option value on the AI-datacenter nuclear theme, and any disappointment in timeline or regulatory progress could compress the multiple sharply.

Historically, Oklo's valuation has been extremely volatile: the price-to-book ratio ranged from 2.82x in Q2 2026 to 13.92x in Q3 2025 and 150.54x in Q4 2021, while the PE ratio has been negative for most periods due to persistent losses. The current PB of 7.11x (as of the Q4 2025 historical data point) sits in the middle of that range but is well below the 13.92x peak, reflecting the recent price collapse; however, the decline in PB is driven by the falling stock price rather than improving book value, and with book value per share of roughly $4.88 (cash per share of $9.33 in Q2 2026), the stock trades at a premium to tangible assets. The historical PS ratio of 7,621x in Q2 2026 is a stark reminder that revenue-based valuation is meaningless at this stage, and the market is effectively pricing Oklo on future cash flows that remain highly uncertain.

Oklo is covered by 20 analysts, with a consensus recommendation of "buy" (recommendation mean of 2.125 on a scale where 1 is strong buy and 5 is strong sell), but the distribution is skewed toward neutral/hold ratings from major firms: UBS, Citigroup, and Truist all maintain Neutral/Hold ratings, while Canaccord Genuity, HC Wainwright, Barclays, Wedbush, and Cantor Fitzgerald carry Buy/Overweight/Outperform ratings. The average target price of $75.78 implies +118.4% upside from the current $34.70 price, a seemingly bullish signal, but the consensus is misleading given the wide dispersion and the fact that targets have not been updated to reflect the recent collapse. The consensus leans cautiously bullish on paper, but the prevalence of Neutral ratings from bulge-bracket banks suggests limited conviction in the near term.

The target range is extraordinarily wide, from a low of $14.00 to a high of $130.00 — a 9.3x spread that signals very high uncertainty about Oklo's future. The high target of $130.00 assumes successful commercialization of the Aurora reactor, regulatory approval, and revenue scaling toward the analyst estimated average of $314.73 million, while the low target of $14.00 prices in further delays, cash burn, and potential dilution that could push the stock below its current 52-week low. Recent institutional actions show no upgrades — UBS, Citigroup, and Truist have all maintained Neutral/Hold ratings through 2026, while Canaccord, HC Wainwright, Barclays, and Wedbush have reiterated Buy/Outperform, indicating a polarized analyst community. The wide spread and lack of recent upgrades suggest the market is in a wait-and-see mode, and with the stock at a 52-week low, the risk of further target cuts remains if commercialization milestones slip.